会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • SUBCUTANEOUS ADMINISTRATION OF ANTI-HEPATITIS B ANTIBODIES
    • 抗生素B抗体的免疫应答
    • WO2010064241A1
    • 2010-06-10
    • PCT/IL2009/001139
    • 2009-12-03
    • OMRIX BIOPHARMACEUTICALS LTD.LAUB, OrgadORR, Nadav
    • LAUB, OrgadORR, Nadav
    • A61K39/42
    • C07K16/082A61K2039/505A61K2039/54C07K16/06
    • The invention relates to the use of a subcutaneous dose of anti-hepatitis B immunoglobulin for hepatitis B therapy. The dose is higher than an intramuscular dose given via the intramuscular route for the same therapy. Such higher subcutaneous dose allows achieving anti-hepatitis B antibodies in the circulation at a similar level and timing as obtained by the intramuscular dose given via the intramuscular route. Advantageously, the subcutaneous dose of anti-hepatitis B of the invention allows rapidly obtaining a predetermined level of anti-hepatitis B antibodies in the circulation such as higher than 100 mIU/ml. The subcutaneous dose of anti-hepatitis B immunoglobulin can be used for prevention of recurrence of hepatitis B following orthotopic liver transplantation (OLT) due to hepatitis B.
    • 本发明涉及皮下剂量的抗乙型肝炎免疫球蛋白用于乙型肝炎治疗的用途。 剂量高于通过肌内途径给予相同疗法的肌内剂量。 这种较高的皮下剂量允许在循环中实现抗乙型肝炎抗体,其通过肌内途径给予的肌内剂量所获得的相似水平和时间。 有利地,本发明的抗乙型肝炎的皮下剂量允许在循环中快速获得预定水平的抗乙型肝炎抗体,例如高于100mIU / ml。 抗乙型肝炎免疫球蛋白的皮下剂量可用于预防乙型肝炎肝移植(OLT)后乙型肝炎复发。
    • 6. 发明申请
    • INTRAVENOUS IMMUNOGLOBULIN COMPOSITION
    • 无菌免疫组织化学
    • WO2007017859A1
    • 2007-02-15
    • PCT/IL2006/000782
    • 2006-07-06
    • OMRIX BIOPHARMACEUTICALS INC.NUR, IsraelBAR, LilianaLAUB, Orgad
    • NUR, IsraelBAR, LilianaLAUB, Orgad
    • C07K16/08A61K39/395A61P31/12
    • C07K16/081A61K38/00A61K39/39591A61K2039/505C07K2319/00
    • A method for preparing a concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, comprising: (a) selecting a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism; (b) determining the level of specific antibodies immunoreactive with the pathogenic microorganism in a blood or blood component of the individuals to identify very high titre individuals having a very high titre of the specific antibodies; (c) combining blood or blood components comprising immunoglobulins from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c), thereby obtaining a concentrated immunoglobulin composition. Also disclosed is a concentrated immunoglobulin composition comprising specific antibodies immunoreactive with a pathogenic microorganism, characterized in that the titre of specific antibodies of the composition is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against one or more antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates, and is therefore suitable for both iv and im administration. In a preferred embodiment, the pathogenic microorganism is smallpox virus or vaccinia virus.
    • 一种制备用于治疗接种疫苗或感染病原微生物的受试者的浓缩免疫球蛋白组合物的方法,包括:(a)选择先前针对与病原微生物相关的一种或多种抗原接种的个体群体; (b)确定在个体的血液或血液成分中与病原微生物免疫反应的特异性抗体的水平,以鉴定具有非常高的特异性抗体滴度的非常高的滴度个体; (c)从非常高的滴度个体组合包含免疫球蛋白的血液或血液成分; 和(d)纯化和/或浓缩步骤(c)的产物,从而获得浓缩的免疫球蛋白组合物。 还公开了包含与病原微生物免疫反应性的特异性抗体的浓缩免疫球蛋白组合物,其特征在于组合物的特异性抗体滴度比先前接种于一种或多种疫苗的个体群体的特异性抗体的平均滴度高至少5倍 更多与病原微生物相关的抗原。 该组合物具有相对高的蛋白质浓度和低百分比的蛋白质聚集体,因此适用于iv和im施用。 在优选的实施方案中,致病微生物是天花病毒或痘苗病毒。